News and analysis on diagnostic technologies and applications.
Top-line results from the first part of the Atalante 1 trial showed the company's investigational product Tedopi produced a 12-month survival rate of 46 percent.
The company announced that it is planning to submit an NDA for the drug in RET-mutant medullary thyroid cancer.
Anetumab ravtansine was well tolerated and there was "a positive trend" suggesting that high mesothelin expression may indicate which cancer patients benefit from BAY 94-9343.
The company is testing out its immune-stimulating antibody conjugate platform technology, hitching its proprietary molecule to trastuzumab.
Under the agreement, AstraZeneca will be able to use ImaginAb's CD8 ImmunoPET technology in its clinical trials in North America and Europe.
